A PET-CT study on neuroinflammation in Huntington's disease patients participating in a randomized trial with laquinimod.

ABSTRACT: Microglia activation, an indicator of central nervous system inflammation, is believed to contribute to the pathology of Huntington's disease. Laquinimod is capable of regulating microglia. By targeting the translocator protein, ¹¹C-PBR28 PET-CT imaging can be used to assess the state of regional gliosis in vivo and explore the effects of laquinimod treatment. This study relates to the LEGATO-HD, multi-centre, double-blinded, Phase 2 clinical trial with laquinimod (US National Registration: NCT02215616). Fifteen patients of the UK LEGATO-HD cohort (mean age: 45.2 ± 7.4 years; disease duration: 5.6 ± 3.0 years) were treated with laquinimod (0.5 mg, N = 4; 1.0 mg, N = 6) or placebo (N = 5) daily. All participants had one ¹¹C-PBR28 PET-CT and

SUBMITTER: Roussakis AA 

PROVIDER: S-EPMC10069663 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature